Vizsgálati helyszín
NZOZ Lecznica MAK MED S C
Nadarzyn, 05 830, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 12futó vizsgálat
- 19lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 32 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis17 vizsgálat
- 2. fázis10 vizsgálat
- 4. fázis3 vizsgálat
- 1. fázis2 vizsgálat
- Állapot
- Lezárult18 vizsgálat
- Fut, nem toboroz8 vizsgálat
- Még nem toboroz2 vizsgálat
- Toboroz2 vizsgálat
- Felfüggesztve1 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC10 vizsgálat
- MoonLake Immunotherapeutics AG3 vizsgálat
- Celltrion Inc.2 vizsgálat
- IGM Biosciences Inc.2 vizsgálat
- Takeda2 vizsgálat
- és még 13
Futó vizsgálatok
Még nem toboroz
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
2026-526538-15-00· 3. fázis· Celltrion Inc.· Forrás
Toboroz
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
2025-523670-17-00· 3. fázis· AstraZeneca AB· Forrás
Toboroz
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· 3. fázis· Janssen Research & Development, LLC· Forrás
Még nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.
2024-516219-25-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462· 2. fázis· Immunovant Sciences GmbH· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076· 3. fázis· Takeda· Forrás
Fut, nem toboroz
Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE
2022-502105-15-00· 2. fázis· Alumis Inc.· Forrás
Fut, nem toboroz
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210· 4. fázis· Janssen Research & Development, LLC· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Fut, nem toboroz
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
NCT06630559· 3. fázis· Celltrion· Forrás
Toboroz
Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis
NCT06833749· 2. fázis· KeyBioscience AG· Forrás
Lezárult
A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
2024-510945-32-00· 3. fázis· Celltrion Inc.· Forrás
Lezárult
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
2024-514981-37-00· 2. fázis· Synact Pharma ApS· Forrás
Lezárult
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren’s Disease
2024-512986-15-00· 2. fázis· Kiniksa Pharmaceuticals GmbH· Forrás
Lezárult
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
2023-506664-14-00· 3. fázis· Dr Reddy's Laboratories Limited· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT06624228· 3. fázis· UCB Biopharma SRL· Forrás
Lezárult
A Phase 1b Study of Imvotamab in Severe Systemic Lupus Erythematosus
2023-506499-29-00· 1. fázis· IGM Biosciences Inc.· Forrás
Lezárult
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
2023-505127-31-00· 1. fázis· IGM Biosciences Inc.· Forrás
Lezárult
Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLANE
2023-505050-18-00· 4. fázis· Charite Universitaetsmedizin Berlin KöR· Forrás
Lezárult
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
NCT06088043· 3. fázis· Takeda· Forrás
Lezárult
A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis
NCT06028438· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis
NCT05248386· 3. fázis· Grünenthal GmbH· Forrás
Lezárult
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
NCT05071664· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
NCT04936308· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus
NCT04882878· 2. fázis· Janssen Research & Development, LLC· Forrás
Leállították
A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
NCT04633447· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
NCT04314544· 3. fázis· Sun Pharmaceutical Industries Limited· Forrás
Lezárult
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
NCT03915964· 4. fázis· Eli Lilly and Company· Forrás
Hibát jelzek